Aurinia Establishes At-The-Market Facility
July 22 2016 - 4:18PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”) today announced that it has entered into a
Controlled Equity Offering Sales Agreement with Cantor Fitzgerald
& Co. (“Cantor”) pursuant to which the Company may from time to
time sell, through at-the-market (“ATM”) offerings with Cantor
acting as sales agent, such common shares as would have an
aggregate offer price of up to US$10,000,000. Aurinia has also
filed a prospectus supplement with securities regulatory
authorities in Canada in the provinces of British Columbia, Alberta
and Ontario, and with the United States Securities and Exchange
Commission, which supplements Aurinia’s short form base shelf
prospectus dated October 16, 2015, and Aurinia’s shelf registration
statement on Form F-10 dated October 16, 2015, declared effective
on November 5, 2015. The listing of any shares sold pursuant to an
ATM offering is subject to the approval of the Toronto Stock
Exchange and NASDAQ. Cantor, at Aurinia’s discretion and
instruction, will use its commercially reasonable efforts to sell
the common shares at market prices from time to time. Sales in an
ATM Offering will only be conducted in the United States through
NASDAQ or another exchange at market prices. No sales will be
conducted in Canada or through the Toronto Stock Exchange.
Aurinia currently intends to use the proceeds from sales related
to the ATM offering, if any, primarily for working capital and
general corporate purposes, including to fund its lupus nephritis
(“LN”) clinical trial program for voclosporin.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualifications under the securities laws of any such
jurisdiction.
Copies of the prospectus supplement and the accompanying
prospectus relating to these securities may be obtained by
contacting Cantor Fitzgerald & Co., Attention: Equity Capital
Markets, 110 East 59th Street, New York, New York 10022, telephone:
212-829-7122.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on
the global nephrology market. The fully-enrolled Phase 2b AURA-LV
clinical trial is evaluating the efficacy of its lead drug,
voclosporin, as a treatment for active LN. LN is an inflammation of
the kidneys, that if inadequately treated can lead to end-stage
renal disease, making LN a serious and potentially life-threatening
condition.
Cautionary Note Regarding Forward-looking Statements
This press release contains forward-looking statements.
Forward-looking statements in this news release include statements
about the possible sales of common shares and statements of the
current intended use of proceeds from the sale of shares, if any.
The forward-looking statements may include, without limitation,
statements that the net proceeds from the sale of the common shares
will be used primarily for working capital and general corporate
purposes, including to fund the LN clinical trial program for
voclosporin. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward looking statements. Such risks and
uncertainties include, among others, the ability of the Company to
protect its intellectual property rights, securing and maintaining
corporate alliances and partnerships, the need to raise additional
capital and the effect of capital market conditions and other
factors on capital availability, the potential of its products, the
success and timely completion of clinical studies and trials, and
the combined company's and its partners' ability to successfully
obtain regulatory approvals and commercialize voclosporin on a
timely basis. These factors should be considered carefully and
readers are cautioned not to place undue reliance on such
forward-looking statements. For additional information on risks and
uncertainties relating to these forward-looking statements,
investors should review the prospectus supplement and accompanying
prospectus and consult the Company's ongoing quarterly filings,
annual reports and the Annual Information Form and other filings
found on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov/edgar.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160722005842/en/
Aurinia Pharmaceuticals Inc.Michael R. Martin, 250-708-4272Chief
Operating Officermmartin@auriniapharma.comorRenmark Financial
Communications Inc.Barry Mire:
bmire@renmarkfinancial.comLaura Welsh:
lwelsh@renmarkfinancial.comTel: (416) 644-2020 or (514)
939-3989